|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
ӲƤ�� |
|
ģ��,���� |
|
�� |
| ��������������� | |
|
��÷ |
|
�˺� |
| PubMed | |
|
Article by JU Mei |
|
Article by GU Heng |
ӲƤ������ģ�͵�Ӧ�ý�չ
��÷, �˺�
�й�ҽѧ��ѧԺƤ�����о��� �Ͼ� 210042
ӲƤ����һ�����������Խ����֯����,����Ӱ�컼�ߵ������������ò��IJ���ͷ���������δ��ȫ����,�ٴ���Ҳ����������Ʒ���,�ڽ��л����о�ʱ������������Խϲ��˽���ӲƤ���Ķ���ģ��,���������о������ķ������ƺ��������Ʒ�������Ҫ���塣������ʮ�������ò�ͬƷϵ����ƶ��ｨ���ĸ���ӲƤ��ģ��,�Լ�������Щģ�ʹӲ�ͬ�ĽǶȲ���ӲƤ�����ܵķ�������,������ҩɸѡ�����Ʒ����۷���ȡ�õ�һЩ��չ��
Application advances in animal models for scleroderma
Institute of Dermatology, Chinese Academy of Medical Science, Nanjing 210042, China
Institute of Dermatology, Chinese Academy of Medical Science, Nanjing 210042, China
Scleroderma is an autoimmune connective tissue disease, and severely affects the life quality of patients. Its exact etiology and pathogenesis are unknown yet and to date, no satisfactory therapy has been found for it. Since patients' low compliance in basic studies, it is very important to establish animal models for further investigation of scleroderma pathogenesis as well as evaluation of therapeutic effect. This review describes several strains of mice model for scleroderma, elucidates the possible pathogenesis of scleroderma from different viewpoints originated from different mice models, and summarizes advances in drug screening and treatment evaluation with these models in the last decade.
[2] Yamamoto T,Takagawa S,Katayama I,et al.Animal model of sclerotic skin.��:Local injections of blcomycin induce sclerotic skin mimicking scleroderma.J Invest Dermatol,1999,112 (4):456-462.
[3] Yamamoto T,Kuroda M,Nishioka K.Animal model of sclerotic skin.��:Histopathological comparison of bleomycin-induced scleroderma in various mice strains.Arch Dermatol Res,2000,292(11):535-541.
[4] Gentiletti J,McCloskey LJ,Artlett CM,et al.Demonstration of autoimmunity in the fight skin-2 mouse:a model for scleroderma.J Immunol,2005,175 (4):2418-2426.
[5] Chatterjee S,Mark ME,Wooley PH,et al.Increased dermal elastic fibers in the tight skin mouse.Clin Exp Rheumatol,2004,22 (5):617-620.
[6] Baxter RM,Crowell TP,McCrann ME,et al.Analysis of the tight skin (Tsk1/+) mouse as a model for testing antifibrotic agents.Lab Invest,2005,85 (10):1199-1209.
[7] Samuel CS,Zhao C,Yang Q,et al.The relaxin gene knockout mouse:a model of progressive scleroderma.J Invest Dermatol,2005,125 (4):692-699.
[8] Ruzek MC,Jha S,Ledbetter S,et al.A modified model of g raft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease.Arthritis Rheum,2004,50 (4):1319-1331.
[9] Yamamoto T.The bleomycin-induced scleroderma model:what have we learned for scleroderma pathogenesis? Arch Dermatol Res,2006,297 (8):333-344.
[10] Wang HW,Tedla N,Hunt JE,et al.Mast cell accumulation and cytokine expression in the tight skin mouse model of scleroderma.Exp Dermatol,2005,14 (4):295-302.
[11] Yamamoto T,Nishioka K.Possible role of apoptosis in the pathogenesis of bleomycin-induced scleroderma.J Invest Dermatol,2004,122 (1):44-50.
[12] Fujimoto M,Hamaguchi Y,Yazawa N,et al.Autoantibodies to a collagen-specific molecular chaperone,heat-shock protein 47,in systemic sclerosis.Clin Exp Immunol,2004,138 (3):534-539.
[13] Matsushita M,Yamamoto T,Nishioka K.Upregulation of inter leukin-13 and its receptor in a murine model of bleomycin-induced scleroderma.Int Arch Allergy Immunol,2004,135 (4):348-356.
[14] Shen Y,Ichino M,Nakazawa M,et al.CpG oligodeoxynucleotides prevent the development of scleroderma-like syndrome in tight-skin mice by stimulating a Th1 immune response.J Invest Dermatol,2005,124 (6):1141-148.
[15] Santiago B,Gutierrez-Canas I,Dotor J,et al.Topical application of a peptide inhibitor of transforming growth factor-betal ameliorates bleomycin-induced skin fibrosis.J Invest Dermatol,2005,125 (3):450-455.
[16] McGaha TL,Phelps RG,Spiera H,et al.Halofuginone,an inhibitor of type-�� collagen synthesis and skin sclerosis,blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts.J Invest Dermatol,2002,118 (3):461-470.
[17] Krause I,Shoenfeld Y.Intravenous immunoglobulin treatment for fibrosis,atherosclerosis,and malignant conditions.Methods Mol Med,2005,109:403-408.
[18] Wu MH,Yokozeki H,Takagawa S,et al.Hepatocyte growth factor both prevents and ameliorates the symptoms of dermal sclerosis in a mouse model of scleroderma.Gene Ther,2004,11(2):170-180.